RT Journal Article
SR Electronic
T1 A Polygenic Risk Score for Coronary Artery Disease Improves the Prediction of Early-Onset Myocardial Infarction and Mortality in Men
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.25.21256083
DO 10.1101/2021.04.25.21256083
A1 Manikpurage, Hasanga D.
A1 Eslami, Aida
A1 Perrot, Nicolas
A1 Li, Zhonglin
A1 Couture, Christian
A1 Mathieu, Patrick
A1 Bossé, Yohan
A1 Arsenault, Benoit J.
A1 Thériault, Sébastien
YR 2021
UL http://medrxiv.org/content/early/2021/04/28/2021.04.25.21256083.abstract
AB Background Several risk factors for coronary artery disease (CAD) have been described, some of which are genetically determined. The use of a polygenic risk score (PRS) could improve CAD risk assessment, but predictive accuracy according to age and sex is not well established.Methods A PRSCAD including the weighted effects of >1.14 million SNPs associated with CAD was calculated in UK Biobank (n=408,422), using LDPred. Cox regressions were performed, stratified by age quartiles and sex, for incident MI and mortality, with a median follow-up of 11.0 years. Improvement in risk prediction of MI was assessed by comparing PRSCAD to the pooled cohort equation with categorical net reclassification index using a 2% threshold (NRI0.02) and continuous NRI (NRI>0).Results From 7,746 incident MI cases and 393,725 controls, hazard ratio (HR) for MI reached 1.53 (95% CI [1.49-1.56], p=2.69e-296) per standard deviation (SD) increase of PRSCAD. PRSCAD was significantly associated with MI in both sexes, with a stronger association in men (interaction p=0.002), particularly in those aged between 40-51 years (HR=2.00, 95% CI [1.86-2.16], p=1.93e-72). This group showed the highest reclassification improvement, mainly driven by the up-classification of cases (NRI0.02=0.199, 95% CI [0.157-0.248] and NRI>0=0.602, 95% CI [0.525-0.683]). From 23,982 deaths, HR for mortality was 1.08 (95% CI [1.06-1.09], p=5.46e-30) per SD increase of PRSCAD, with a stronger association in men (interaction p=1.60e-6).Conclusion Our PRSCAD predicts MI incidence and all-cause mortality, especially in men aged between 40-51 years. PRS could optimize the identification and management of individuals at risk for CAD.Competing Interest StatementBJA is a consultant for Novartis and Silence Therapeutics and has received research funding from Pfizer and Ionis Pharmaceuticals. PM is a consultant for Casebia Therapeutics.Funding StatementBJA and ST hold junior scholar awards from the FRQS. YB holds a Canada Research Chair in Genomics of Heart and Lung Diseases. PM holds a FRQS Research Chair on the Pathobiology of Calcific Aortic Valve Disease. This work was supported by a grant from the Canadian Institutes of Health Research (PJT-162344) to ST.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Analyses performed with the UK Biobank dataset were conducted under UK Biobank data application number 25205. This project was approved by the IRB of the Quebec Heart and Lung Institute.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData that support our findings are available through appropriate application to UK Biobank (UKB).Data access permission for this study was granted under UKB application 25205. Computational codes are available, without compromising sensitive individual-level data, from the corresponding author upon reasonable request.